NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis $1.26 +0.04 (+3.28%) As of 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Milestone Pharmaceuticals Stock (NASDAQ:MIST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MIST alerts:Sign Up Key Stats Today's Range$1.20▼$1.2950-Day Range$1.04▼$1.3652-Week Range$1.00▼$3.06Volume1.57 million shsAverage Volume1.87 million shsMarket Capitalization$156.87 millionP/E RatioN/ADividend YieldN/APrice Target$7.25Consensus RatingModerate Buy Company Overview Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma. Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs. Preclinical and early clinical studies are aimed at demonstrating safety, tolerability and proof of concept in patient populations with high unmet medical need. The company leverages strategic collaborations and research partnerships to accelerate development and expand its scientific expertise. Founded in the United States and headquartered in San Diego, California, Milestone Pharmaceuticals operates with a management team experienced in respiratory drug development. The company continues to pursue regulatory pathways for its lead programs and is preparing for later-stage clinical trials. Through a combination of internal innovation and external partnerships, Milestone seeks to bring new treatment options to patients suffering from debilitating respiratory disorders.AI Generated. May Contain Errors. Read More Milestone Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreMIST MarketRank™: Milestone Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat, and ranked 719th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMilestone Pharmaceuticals has a consensus price target of $7.25, representing about 477.7% upside from its current price of $1.26.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.83) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Milestone Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.34% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 13.59, which indicates bearish sentiment.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 15.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Milestone Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest21 people have searched for MIST on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.03% of the stock of Milestone Pharmaceuticals is held by insiders.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIST Stock News HeadlinesBrokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) PT at $7.25August 7 at 3:31 AM | americanbankingnews.comMilestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026August 4, 2026 | globenewswire.comBofA: Digital Dollar Coming 2025-2030If you've got $50k+ sitting in a bank account, you need to hear this. There's a plan to merge every dollar you own, every transaction you make, and every asset you hold onto ONE global ledger. Back in 2020 they said the quiet part out loud... "The central bank will have absolute control." The plan is one global ledger. Every dollar you own... Every transaction you make... All on one platform. Visible. Programmable. But here's what they don't tell you... A loophole already exists that allows you to opt out. A parallel system, outside the traditional banking rails. Outside the ledger. Visa moved billions of transactions onto it last year. PayPal built its entire new payment layer on top of it. BlackRock chose it as the home for their first tokenized fund. The people who run the system... are quietly stepping outside it.August 10 at 1:00 AM | Decentralized Masters (Ad)Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comMilestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks TranscriptJune 10, 2026 | seekingalpha.comMilestone Pharmaceuticals: Here Comes The Revenue RampJune 9, 2026 | seekingalpha.comMilestone Pharmaceuticals: Taking The Long ViewJune 5, 2026 | seekingalpha.comMilestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2026 | finance.yahoo.comSee More Headlines MIST Stock Analysis - Frequently Asked Questions How have MIST shares performed this year? Milestone Pharmaceuticals' stock was trading at $2.02 at the beginning of 2026. Since then, MIST shares have decreased by 37.9% and is now trading at $1.2550. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) posted its earnings results on Wednesday, May, 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.26. The company earned $0.24 million during the quarter, compared to the consensus estimate of $30.12 million. Read the conference call transcript. When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $82 million in an IPO on Thursday, May 9th 2019. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Top institutional shareholders of Milestone Pharmaceuticals include Bay Rivers Group (0.04%). Insiders that own company stock include Joseph Oliveto, Lorenz Muller, David Bharucha and Jeffrey Edward Nelson. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray Brands (TLRY), VBI Vaccines (VBIV), Aquestive Therapeutics (AQST). Company Calendar Last Earnings5/13/2026Today8/10/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 MIST's financial health is in the Yellow zone, according to TradeSmith. MIST has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MIST CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees30Year Founded2005Price Target and Rating Average Price Target for Milestone Pharmaceuticals$7.25 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+477.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.06 million Net MarginsN/A Pretax Margin-3,933.43% Return on Equity-339.33% Return on Assets-61.79% Debt Debt-to-Equity Ratio1.61 Current Ratio9.18 Quick Ratio9.09 Sales & Book Value Annual Sales$1.55 million Price / Sales100.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book3.22Miscellaneous Outstanding Shares124,500,000Free Float118,236,000Market Cap$156.25 million OptionableOptionable Beta0.98 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MIST) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe ultimate IPO unicornAnthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...Weiss Ratings | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | SponsoredBofA: Digital Dollar Coming 2025-2030Why does the Fed keep denying a digital dollar... when the framework for "programmable money" is already publi...Decentralized Masters | SponsoredA $5 stock inside Kennedy Space Center?A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
